The editors have been colleagues for more than 25 years and have been involved in the design and coordination of clinical trials and multimodality approaches for children with Hodgkin and non-Hodgkin lymphomas. Progress in elucidating the pathogenesis and in the diagnosi and treatment of lymphomas in
children has been one of the great success stories in pediatric oncology. Prior to 1970, fewer than 20% of children with malignant lymphomas survived. Today, more than 90% of children diagnosed with Hodgkin lymphoma survive and more than 80% of children with non-Hodgkin lymphoma are considered cured. Continued improvement in survival has occurred as the result of combination chemotherapy, multidisciplinary care, supportive care and new insights into lymphoma biology.
children has been one of the great success stories in pediatric oncology. Prior to 1970, fewer than 20% of children with malignant lymphomas survived. Today, more than 90% of children diagnosed with Hodgkin lymphoma survive and more than 80% of children with non-Hodgkin lymphoma are considered cured. Continued improvement in survival has occurred as the result of combination chemotherapy, multidisciplinary care, supportive care and new insights into lymphoma biology.
In addition, the rarity of childhood lymphoma has fostered national and international collaborations to test new therapies and to better understand the molecular biology of lymphomas that occur in children. Our first edition of Pediatric Lymphomas provides comprehensive chapters on the diagnosis and treatment of both Hodgkin and non-Hodgkin lymphomas, and lymphoproliferative disorders associated with immunodeficiency. In addition, three chapters focus on the pathology, molecular biology, and genetics of Hodgkin and non-Hodgkin lymphoma including the rare cutaneous lymphomas. We hope that Pediatric Lymphomas will be a useful resource for practitioners from the many diff erent disciplines involved in the comprehensive care of children with lymphomas.
Th e authors are all leading experts in the area of childhood lymphomas. We wish to thank them for all of the time and eff ort that went into their contributions. If this fi rst edition is helpful to our diverse readership, it is because of the authors. We also want to acknowledge our desk editor, Meike Stoeck, and our partnership with Springer.
As pediatric oncologists, we are dedicated to improving the lives of children facing malignancy. We hope this book contributes to the fi eld of pediatric oncology and to the benefi t of our patients and their families.
Th e authors are all leading experts in the area of childhood lymphomas. We wish to thank them for all of the time and eff ort that went into their contributions. If this fi rst edition is helpful to our diverse readership, it is because of the authors. We also want to acknowledge our desk editor, Meike Stoeck, and our partnership with Springer.
As pediatric oncologists, we are dedicated to improving the lives of children facing malignancy. We hope this book contributes to the fi eld of pediatric oncology and to the benefi t of our patients and their families.
0 comments:
Post a Comment